New Product Launch BIOPONIB®ponatinib

26/04/2023

Bioprofarma Bagó is pleased to present the launch of BIOPONIB® ponatinib for its Hematology Business Unit.

BIOPONIB® ponatinib is approved by ANMAT for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL) in adult patients who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and in whom subsequent treatment with imatinib is not clinically indicated; or who present the T315I mutation.

HOW SUPPLIED:

BIOPONIB® 15 mg x 30 coated tablets
BIOPONIB® 15 mg x 60 coated tablets
BIOPONIB® 45 mg x 60 coated tablets

BIOPONIB® ponatinib joins the portfolio of products for the treatment of CML and ALL PH+, together with CLINID®imatinib and DAPIBUS® dasatinib.

This new treatment alternative comes to provide specialists with more options for the care of their patients.

New Product Lunch IMPILO®bexarotene

Bioprofarma Bagó replaces TARGRETIN® with IMPILO®bexarotene.

Read note

(Español) Nuevo lanzamiento HUTUS® enzalutamida

(Español) Nos complace presentarles nuestro nuevo producto HUTUS® enzalutamida para cáncer de próstata

Read note

XXVI Argentine and International Congress of Clinical Oncology organized by the AAOC

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at La Rural, in the City of Buenos Aires, and Bioprofarma Bago was there.

Read note